Izuralimab is a monoclonal antibody commercialized by Xencor, with a leading Phase I program in Adenocarcinoma Of The Gastroesophageal Junction. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Izuralimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Izuralimab is expected to reach an annual total of $97 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Izuralimab Overview

XmAb-23104 is under development for the treatment of melanoma, cervical carcinoma, pancreatic cancer, advanced or metastatic melanoma, breast cancer, hepatocellular carcinoma, urothelial cell carcinoma, squamous cell carcinoma of the head and neck, nasopharyngeal cancer, colorectal cancer, sarcoma, endometrial cancer, non-small cell lung carcinoma, small-cell lung cancer, gastric cancer and gastroesophageal junction adenocarcinoma. The drug candidate is a bi-specific monoclonal antibody that acts by targeting programmed cell death protein 1 (PD-1) and T cell co-stimulatory receptors. It is administered through intravenous route. It is based on XmAb bi-specific/Xtend Fc domains antibody engineering technology.

Xencor Overview

Xencor is a clinical stage biopharmaceutical company that focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Its Plamotamab is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates. . Xencor is headquartered in Monrovia, California, the US.

The company reported revenues of (US Dollars) US$275.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$122.7 million in FY2020. The operating profit of the company was US$43 million in FY2021, compared to an operating loss of US$76.8 million in FY2020. The net profit of the company was US$82.6 million in FY2021, compared to a net loss of US$69.3 million in FY2020. The company reported revenues of US$27.3 million for the third quarter ended September 2022, a decrease of 9.5% over the previous quarter.

For a complete picture of Izuralimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.